AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02067195
Drug: 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP \<13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and \>1.5 ml/kg/hr for LVEDP \>18 mmHg, whereas,0.5 ml/kg/hr for LVEDP \>20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
Trial: NCT01398020
Drug: Standard Bowel Prep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to take 4L of Peglyte the day prior to procedure.
Trial: NCT02109562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
Trial: NCT00000883
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03539328
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy medication
Trial: NCT00555230
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Trial: NCT00555230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Trial: NCT02678143
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01809171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ampoule
Trial: NCT03487107
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet administered orally once daily
Trial: NCT03487107
Drug: DAG181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsule administered orally once daily
Trial: NCT02344992
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Trial: NCT01051505
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
Trial: NCT01051505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
Trial: NCT03266237
Drug: Vaxigrip®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
Trial: NCT03166735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00322803
Drug: ELB139
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01989091
Drug: Heparin 5,000 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Catheter Lock Solution
Trial: NCT01490944
Drug: Iron and Folic Acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
Trial: NCT00148681
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every 3 weeks for 12 weeks
Trial: NCT00148681
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously every 3 weeks for 12 weeks
Trial: NCT01728909
Drug: Saline Nasal Spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Trial: NCT02958111
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
Trial: NCT01781637
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT01099137
Drug: Sulphonylurea dose-up
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
Trial: NCT00584298
Drug: SMS995
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00584298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03354026
Drug: AICH-PXZY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
Trial: NCT03354026
Drug: AICH-without PXZY
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
Trial: NCT03354026
Drug: AICH-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is made up of Starch, bitter taste and cyclodextrin
Trial: NCT01085045
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo administered as two puffs BID for 7 days
Trial: NCT04223895
Drug: CKD-386 Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 1 tablet under fasting conditions for each period
Trial: NCT04223895
Drug: D012, D326 and D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
Trial: NCT02245438
Drug: Norethindrone-Ethinyl Estradiol
RxNorm normalized name: norethindrone-ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02592551
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
Trial: NCT02839408
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet containing 500mg Azithromicyn
Trial: NCT04669132
Drug: Palonesetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Palonosetron 0.56 mg, once daily, on chemotherapy day;
Trial: NCT01519271
Drug: Placebo Patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
Trial: NCT01458912
Drug: Placebo matching Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs a.m. via Respimat inhaler
Trial: NCT00803764
Drug: Naproxen Tablets, 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02303548
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02576353
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl Sublingual Spray (FSS)
Trial: NCT02576353
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl Citrate IV (FCIV)
Trial: NCT01361802
Drug: Placebo Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Spray
Trial: NCT02321384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
Trial: NCT02321384
Drug: RO6889678
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
Trial: NCT04091854
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
Trial: NCT00218205
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02400047
Drug: Ketoprofen 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
Trial: NCT02012244
Drug: fentanyl-based analgesia
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
Trial: NCT01377025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tablets in the morning and two in the evening.
Trial: NCT04512053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for 12 weeks, once daily
Trial: NCT01631981
Drug: Placebo + Primolut-Nor 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up.
Trial: NCT01731990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of Canakinumab
Trial: NCT04426669
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
Trial: NCT01667536
Drug: Drug: 99mTc-MIP-1404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
Trial: NCT02171754
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00795015
Drug: insulin regular IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
Trial: NCT00979706
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year.
Trial: NCT00979706
Drug: HAART + Immunotherapy
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year.
Trial: NCT01950247
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01203878
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 4 weeks after completion of imiquimod therapy
Trial: NCT03277742
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOTS plus standard DM2 care
Trial: NCT04205968
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV bolus or IV
Trial: NCT04205968
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04205968
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02679014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
Trial: NCT02679014
Drug: RO5459072
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
Trial: NCT01471093
Drug: OPC-12759 Ophthalmic solution
RxNorm normalized name: Opcon-A Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2％ OPC-12759 Ophthalmic solution
Trial: NCT01471093
Drug: OPC-12759 Ophthalmic suspension
RxNorm normalized name: Opcon-A Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2％ OPC-12759 Ophthalmic suspension
Trial: NCT01735279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
Trial: NCT02841488
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of patient controlled analgesia device with intravenous fentanyl
Trial: NCT01538251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
Trial: NCT03105830
Drug: iv paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv paracetamol
Trial: NCT02671435
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of mFOLFOX as stated in arm description.
Trial: NCT01848301
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion in the coronary artery to study endothelial function
Trial: NCT02293083
Drug: trigger point injection
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00193284
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03097900
Drug: Caffeine Citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
Trial: NCT04666636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
Trial: NCT00912288
Drug: Placebo po TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched to Dimebon) po for 26 weeks
Trial: NCT02992678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
Trial: NCT03755609
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1ug/kg intravenously
Trial: NCT03340727
Drug: Caffeine Citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
Trial: NCT03340727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
Trial: NCT00619970
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo TID x 10days
Trial: NCT03078075
Drug: Placebo (PLB) Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: once-daily oral placebo tablets
Trial: NCT01299376
Drug: L50/H12.5/A5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01299376
Drug: L50/H12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01299376
Drug: Placebo to L50/H12.5/A5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01299376
Drug: Placebo to L50/H12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240981
Drug: Topical testosterone gel 1% (active formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
Trial: NCT02989389
Drug: LY3323795
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04067102
Drug: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
Trial: NCT04067102
Drug: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
Trial: NCT02989389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00988026
Drug: Minocycline vs Lymecycline
RxNorm normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
Trial: NCT02300948
Drug: PregVit® contains 1.1 mg of folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
Trial: NCT02300948
Drug: PregVit-folic 5® contains 5 mg of folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
Trial: NCT00528580
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg once daily PO/NG x 4 days
Trial: NCT03472365
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
Trial: NCT00957047
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily placebo comparator